Bovine conglutinin is a collagen-like protein.

Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest (1992) 2.04

Two distinct serum mannose-binding lectins function as beta inhibitors of influenza virus: identification of bovine serum beta inhibitor as conglutinin. J Virol (1992) 1.56

Purification, characterization and cDNA cloning of human lung surfactant protein D. Biochem J (1992) 1.33

Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q. Biochem J (1991) 1.29

Human mannan-binding lectin inhibits the infection of influenza A virus without complement. Immunology (1999) 1.13

Bovine serum conglutinin is a lectin which binds non-reducing terminal N-acetylglucosamine, mannose and fucose residues. Biochem J (1989) 1.06

Ultrastructure and composition of bovine conglutinin. Biochem J (1986) 1.02

Partial characterization of a low molecular weight human collagen that undergoes alternative splicing. Proc Natl Acad Sci U S A (1987) 0.95

The cDNA cloning of conglutinin and identification of liver as a primary site of synthesis of conglutinin in members of the Bovidae. Biochem J (1993) 0.77

The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40

Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92

Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29

CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19

Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J Immunol (1985) 3.97

AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53

Recurrent Retinal Hemorrhages Occurring in the Young, with the Report of a Case. Trans Am Ophthalmol Soc (1912) 3.44

The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41

Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16

Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89

Deficiency of C3 inactivator in man. J Immunol (1971) 2.86

Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84

Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81

Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77

The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66

Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60

Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59

The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50

Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38

Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36

Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20

The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16

Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol (1985) 2.07

Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med (1983) 2.07

Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04

Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00

Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody. J Clin Microbiol (1979) 1.97

A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95

The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94

The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93

Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93

The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92

Structural and functional division into two domains of the large (100- to 115-kDa) chains of the clathrin-associated protein complex AP-2. Proc Natl Acad Sci U S A (1989) 1.91

Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91

The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88

Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79

Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76

Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome. Proc Natl Acad Sci U S A (1989) 1.73

The chemotactic activity for neutrophil and eosinophil leucocytes of the trimolecular complex of the fifth, sixth and seventh components of human complement (C567) prepared in free solution by the 'reactive lysis' procedure. Immunology (1970) 1.73

Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71

The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68

Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64

Identification of Ss protein as murine C4. Nature (1975) 1.63

Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63

Deficiency of factor B of the complement system in sickle cell anaemia. Br Med J (1976) 1.61

The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60

The behaviour of complement and platelets in lethal endotoxin shock in rabbits. Int Arch Allergy Appl Immunol (1973) 1.60

The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol (1968) 1.58

Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins. Int Arch Allergy Appl Immunol (1965) 1.56

Complement genetics in relation to HLA. Br Med Bull (1978) 1.55

Initiation of complement activation. Springer Semin Immunopathol (1984) 1.54

A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol (1977) 1.50

The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol (1978) 1.47

The prevention of hospitalization in schizophrenia: five years after an experimental program. Am J Orthopsychiatry (1972) 1.45

Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1. Blood (1985) 1.44

The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43

Deficiency of the second component of complement associated with anaphylactoid purpura and presence of mycoplasma in the serum. Clin Exp Immunol (1973) 1.42

Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology (1970) 1.42

Evaluation of the Honeywell ACS 1000. Am J Med Technol (1977) 1.40

Studies on the terminal stages of complement lysis. Immunology (1973) 1.40

Combined genetic deficiency of C6 and C7 in man. Clin Exp Immunol (1978) 1.38

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol (1995) 1.37

Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol (1978) 1.37

An iatrogenic autoantibody: immunological responses to 'pituitary snuff' in patients with diabetes insipidus. Clin Exp Immunol (1966) 1.35

Immunoconglutinins in human saliva--a group of unusual IgA antibodies. Immunology (1970) 1.35

Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35

Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci U S A (1977) 1.34

Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure (1994) 1.34

An improved purification procedure for the third component of complement and beta 1H globulin from human serum. Mol Immunol (1979) 1.34

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33

Purification and chemical composition of gpL115, the human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome. J Biol Chem (1986) 1.33

Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol (1984) 1.32

Immunity deficiency in pathogenesis of glomerulonephritis. Lancet (1974) 1.31

Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology (2001) 1.31

Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol (1990) 1.29

Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol (1976) 1.28

Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals. Ciba Found Symp (1986) 1.28

Double-blind trial of cholestyramine in post-vagotomy diarrhoea. Gut (1977) 1.28

Allotypes of complement components in man. Transplant Rev (1976) 1.27

Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J Virol (1996) 1.27

Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans. J Clin Invest (1977) 1.26

Inherited structural variation and linkage relationships of C7. J Immunogenet (1978) 1.26

Purification of cobra venom factor from phospholipase A contaminant. Immunology (1976) 1.25

Measles virus receptor on human T lymphocytes. Nature (1975) 1.24

The fractionation of antigen-dependent macrophage migration inhibition and macrophage activation factors from lymph draining a tuberculin reaction. Scand J Immunol (1974) 1.24

Inherited deficiencies of the terminal components of human complement. Immunodefic Rev (1992) 1.24

The paraproteins in systemic capillary leak syndrome. Clin Exp Immunol (1993) 1.22

Lymphocyte cooperation. Proc R Soc Lond B Biol Sci (1971) 1.21

Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arthritis Rheum (1988) 1.21

The effect of diet on lactase activity in the rat. Gastroenterology (1971) 1.19

The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation. Eur J Immunol (1988) 1.18

Restoration of specific immunological virginity. Nature (1974) 1.16

Consent and confidentiality--where are the limits? An introduction. J Med Ethics (2003) 1.15

Cellular immunity in subacute sclerosing panencephalitis. Proc R Soc Med (1974) 1.14

Lesions due to complement in lipid membranes. Nature (1971) 1.13

Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. J Clin Invest (1975) 1.11

Biosynthesis of complement by human monocytes. Clin Immunol Immunopathol (1981) 1.10

Liver disease and cell-mediated immunity in hepatitis-associated antigen (HAA) carriers. Gut (1973) 1.10

Structural characterization of factor I mediated cleavage of the third component of complement. Biochemistry (1982) 1.09